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ABSTRACT: 
 
An incompletely penetrant COL7A1 mutation causes dystrophic epidermolysis bullosa 
and epidermolysis bullosa pruriginosa. 
 
Catherine S. Yang B.A.a, Yin Lu Ph.D.b, Anita Farhi R.N.b, Carol Nelson-Williams 
Ph.D.b, Michael Kashgarian M.D.c, Earl J. Glusac M.D.c, Richard P. Lifton M.D. 
Ph.D.b, Richard J. Antaya M.D.d, Keith A. Choate M.D. Ph.D.b,d. 
 
a Yale University School of Medicine, New Haven, CT.  
b Department of Genetics, Howard Hughes Medical Institute, New Haven, CT. 
c, d Departments of Pathology and Dermatology, Yale University School of Medicine, 
New Haven, CT.  
 
 
Epidermolysis bullosa pruriginosa (EBP) is a rare subtype of dystrophic 
epidermolysis bullosa (DEB) and is characterized by intense pruritus, nodular or 
lichenoid lesions, and violaceous linear scarring most prominent on the extensor 
extremities. Remarkably, identical mutations in COL7A1, which encodes an 
anchoring fibril protein present at the dermal-epidermal junction, can cause both DEB 
and EBP with either autosomal dominant or recessive inheritance. We present one 
family with both dystrophic and pruriginosa phenotypes of epidermolysis bullosa. The 
proband is a 19-year-old Caucasian female who initially presented in childhood with 
lichenoid papules affecting her extensor limbs and intense pruritus consistent with 
EBP. Her maternal grandmother was followed by a dermatologist for similar skin 
lesions that developed without any known triggers at age 47 and mostly resolved 
spontaneously after approximately ten years. The proband’s younger brother 
developed a small crop of pruritic papules on his elbows, dorsal hands, knees, and 
ankles at age 13. Her second cousin once removed, however, report a mild blistering 
disease without pruritus consistent with DEB. Genetic sequencing of the kindred 
revealed a single dominant novel intron 47 splice site donor G>A mutation, c.4668+1 
G>A, which we predict leads to exon skipping. Incomplete penetrance is confirmed in 
her clinically-unaffected mother, who also carries the same dominant mutation. The 
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wide diversity of clinical phenotypes with one underlying genotype demonstrates that 
COL7A1 mutations are incompletely penetrant and strongly suggests that other 
genetic and environmental factors influence clinical presentation. 
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INTRODUCTION: 
The broad term ‘epidermolysis bullosa’ (EB) was first coined by German 
dermatologist Heinrich Koebner in 1866 to describe a group of inherited trauma-
induced blistering disorders. Since its introduction, EB has been stratified into three 
subtypes depending upon the ultrastructural findings on electron microscopy: 1) EB 
simplex, denoting non-scarring blistering at the level of the epidermis; 2) junctional 
EB for blistering at the level of the lamina lucida; and 3) dystrophic EB (DEB) for 
scarring blisters at the level of the sub-lamina densa. A recent addition to the EB 
family in 2008 is Kindler's syndrome, a separate entity because its blistering can 
occur at any of the three cleavage planes (1). EB is a relatively common, prototypical 
genodermatosis with an estimated prevalence of 8.22 per 1 million people worldwide 
(2), although some believe this number to be an underestimate that does not capture 
many individuals falling within the milder spectrum of DEB (3). 
  
DEB is a clinically heterogenous class of diseases that is caused by both dominant and 
recessive mutations in type VII collagen, the major anchoring fibril located below the 
basal lamina. Generalized dominant DEB, a term encompassing both Cockayne-
Touraine and Pasini-type DEB, tends to produce a mild phenotype of localized 
blistering at sites of trauma that heal with milia and atrophic scarring. In some 
patients, the only manifestation of dominant DEB is isolated nail dystrophy or sub-
clinical blistering. Severe generalized recessive DEB (RDEB-sev gen, previously 
Hallopeau-Siemens RDEB), on the other hand, often presents with whole-body 
blisters and extracutaneous manifestations such as excessive dental caries, esophageal 
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strictures, and colitis. These patients suffer from painful and mutilating contractures 
and have a shortened lifespan due to repeated infections or frequent, aggressive 
squamous cell carcinomas. An intermediate form named recessive DEB generalized 
other (RDEB-O, previously non-Hallopeau-Siemens RDEB or RDEB-mitis) also 
demonstrates extensive blistering and extracutaneous involvement but is a milder 
phenotype than RDEB-sev gen with decreased mortality. In addition to these three 
common subtypes of DEB, there are at least five other, rarer forms of DEB including 
epidermolysis bullosa pruriginosa (1). 
 
Epidermolysis bullosa pruriginosa (EBP) was first described by McGrath et al in 1994 
(4) and is distinguished from other types of DEB by its intense pruritus, lichenified or 
nodular prurigo-like lesions, and violaceous linear scarring. Blisters and erosions, 
which are the hallmark features of DEB, are rarely seen in EBP. The extensor 
extremities, particularly the shins, are commonly affected sites. Excoriations, milia, 
albopapuloid lesions, and nail dystrophy are often apparent whereas teeth and 
mucosal membranes are usually unaffected. Extracutaneous manifestations are 
extremely rare; only one EBP patient with gastrointestinal involvement has been 
reported in the literature thus far (5). Unlike DEB, which often manifests at birth, 
many cases of EBP do not present until adulthood (5–10). The oldest reported age of 
onset is 71 years (11). As such, EBP can be mistaken for acquired disorders such as 
prurigo nodularis, lichen simplex chronicus, hypertrophic lichen planus, or 
psychogenic pruritis. 
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A. Molecular processing of collagen VII  
All forms of DEB, including EBP, are caused by mutations in the gene encoding for 
type VII collagen, COL7A1. The COL7A1 gene, located on chromosome 3p21, 
contains 32 kilobases (12). The gene is transcripted into an 8.9 kb mRNA product, 
which is then translated into a 2944 amino acid proα1 polypeptide (13). The protein 
consists of three domains: a large non-collagenous (NC-1) domain from exon 1 to 28, 
a triple helical glycine-X-Y repeat domain from exon 29 to 111 with several short 
interruptions, and a smaller non-collagenous (NC-2) domain from exon 112-118. In 
the extracellular matrix, three proα1 polypeptides assemble into a collagen VII 
homotrimer. Two homotrimers form an antiparallel dimer and an aggregate of dimers 
assemble into anchoring fibrils with intermolecular disulphide bonds and 
transglutaminase cross-links for stabilization (14). The NC-1 domain on both ends of 
the anchoring fibrils adheres to the basement membrane above and the collagen IV 
fibrils in the dermis below (12,13). 
  
Over 300 mutations in COL7A1 have been identified in patients with DEB (12,15) 
and there appears to be some genotype to phenotype correlation. Typically, missense 
mutations and in-frame splice site mutations, deletions, and insertions are dominantly 
inherited while mutations resulting in premature termination codons (PTCs) are 
recessively inherited. Dominant DEB, which has milder clinical phenotypes, usually 
shows normal quantity and/or appearance of anchoring fibrils on biopsy. These 
mutations cause qualitative changes such as disrupting the correct processing of 
collagen VII or decreasing the stability of the anchoring fibrils. Recessive DEB, 
however, is more severe, with decreased amounts of collagen VII apparent on electron 
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microscopy and immunofluorescence staining. Patients with RDEB-sev gen typically 
possess two PTCs leading to no functional protein whereas RDEB-O contain one PTC 
and one missense mutation or two missense mutations causing malfunctioning or 
absent anchoring fibrils at the dermal epidermal junction (12). Hence, as expected, the 
severity of the DEB depends on the amount of collagen VII present. 
  
Comparatively, over 50 mutations in COL7A1 have been reported in EBP. The 
majority of the mutations are dominant missense alterations in the amino acid glycine 
within the triple helical domain, although exceptions exist (5,6,9). The 
immunofluorescence pattern in EBP typically resembles that of DDEB, with staining 
similar to normal skin or slightly decreased. No clear pattern of mutations leading to 
EBP emerges, but exon 87 skipping in particular has been suggested as predictive for 
EBP (10,16–18). At least six mutations either within the splice site donor or within 
exonic regulatory sequences have been identified in families with EBP (9–11,16–20). 
However, exon 87 skipping has also been described in dominant DEB (21) and has 
more recently been suggested to be prognostic for a mild phenotype of DEB rather 
than specifically EBP (22).  
  
B. Hypotheses regarding the etiology of the pruritus in EBP  
The cause of pruritus in EBP is unknown. Remarkably, the identical mutation in 
COL7A1 can cause DEB in one patient and EBP in another (5–9,23).  Alternate 
hypotheses regarding the origin of pruritus have included elevated serum IgE levels 
(9,20,24), concurrent filaggrin mutations leading to atopy (5), increased expression of 
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matrix metalloproteinase 1 (MMP1) causing imbalance of collagen degradation 
(10,25), and increased cytokine IL-31 (26). None of these hypotheses uniformly 
accounts for pruritus observed in EBP.  A more thorough discussion of these theories 
is presented below.  
 
i.                 Elevated serum IgE levels 
Elevated serum IgE levels initially seemed like a promising correlation with the 
hallmark pruritus of EBP. Early case reports had noted elevated IgE levels in their 
patients (24,27). In one study, seven out of nine patients studied had elevated IgE 
levels, several with values threefold higher than the upper limit of normal (20). 
However, in a 2006 study by Drera et al, only two out of seven EBP patients had 
elevated IgE levels (9). Furthermore, in a control group of patients with non-pruritic 
DEB, two out of six also had elevated IgE and thus the marker proved to be poorly 
specific for EBP (20). In subsequent reports, it quickly became apparent that the link 
between hyper-IgE levels and EBP was tenuous at best, as the overwhelming majority 
of patients with EBP have normal IgE levels (5,16,17). 
 
ii.               Co-existing pruritic disorder 
The initial correlation between IgE levels and EBP induced a discussion of whether 
these patients possessed an atopic diathesis. In the initial report by McGrath et al, 
only one of the seven patients presented had a history of eczema, asthma, or 
rhinoconjunctivitis (4). Among the patients with elevated IgE levels reported in other 
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case series, several had either a personal or family history of atopic disease (27), but 
most were unexplained (9,20,28). Yet, in many instances, adequately treating the 
atopy with corticosteroids induced improvement in the patient’s cutaneous lesions of 
EBP as well (9,27). 
 
Other etiologies of pruritus such as thyroid dysfunction, cholestasis, end stage renal 
disease, iron deficiency, and Hodgkin’s lymphoma are routinely screened for and 
rarely found (4,9,20). However, many patients recall mild DEB that evolve into EBP, 
often attributing this to the onset of pruritus due to an external cause such as 
pregnancy, thyroid cancer, diabetes mellitus, or even varicella virus infection 
(5,6,8,11) although correction of these diseases did not lead to improvement of their 
cutaneous lesions. An interesting observation is the onset of pruritus with onset of 
puberty, suggesting a possible modifying role for the hormonal cascades associated 
with adolescence acting as a trigger (9,29). However, many others report 
improvement of their lesions during puberty (6,18) and thus again, no clear pattern 
emerges. 
 
iii.             Filaggrin mutations 
For years, mutations in filaggrin, a protein integral to an intact skin barrier, was 
suspected to predispose children to atopic dermatitis and ichthyosis vulgaris (30), but 
further characterization of this association proved elusive due to the highly repetitive 
sequences precluding sequencing until 2007 (31). This seminal paper documented two 
filaggrin variants with a prevalence of approximately 9% in the European population 
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and three additional less common variants that cumulatively accounted for another 
2.6% (30,31). Schumann et al postulated that mutations in filaggrin may further 
compromise the skin barrier and thus correlate with the pruritus of EBP (5). They 
screened seven patients with EBP for the two most common filaggrin variants in the 
European population, R501X and 2282del4, but found neither in all of the patients.  
 
iv.             Matrix metalloproteinase-1 expression 
Matrix metalloproteinase-1 (MMP1) degrades extracellular proteins such as type VII 
collagen and is integral to tissue remodeling and wound healing. Titeux et al 
described a polymorphism in the gene promoter of MMP1 that increases its 
expression, leading to more severe RDEB than those who did not carry the 
polymorphism (25). The addition of a nucleotide G creates a new ETS transcription 
binding site in the promoter, thus enhancing the expression of MMP1. Almaani et al 
postulated that the increased degradation of type VII collagen by MMP1 could lead to 
secondary inflammatory changes causing pruritus (32). They screened a cohort of 27 
patients with EBP, 23 patients with DDEB, 25 patients with RDEB, and 50 control 
subjects for the MMP1 promoter polymorphism, rs1799750: (-)>G. Although the 
researchers found a higher frequency of the 2G allele in RDEB group, there was no 
significant difference between the 1G and 2G MMP1 alleles among the EBP, DDEB, 
and control groups (32). 
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v.               Immunomodulatory factors 
Given the success of immunomodulatory agents such as cyclosporine and tacrolimus 
in the treatment of EBP, a hypothesis regarding the effect of cytokines and other 
immunomodulatory factors has been proposed (9,33).  Overexpression of cytokine 
interleukin-31 (IL-31) has been found to be upregulated in patients with atopic 
dermatitis and also to induce severe itching and eczema in mice (34,35). 
Polymorphisms within cytokine IL-31 has been linked to increased stimulation of T-
cell antibodies and hence, eczema susceptibility (36). Using the same cohort of EBP, 
DDEB, RDEB, and unaffected patients described above in ‘iv’ (32), the group tested 
the IL-31 haplotype and again found no statistically significant differences in allele 
frequencies. However, the authors readily admit the limitations of their study, which 
only examined the genetic sequence and did not measure the amount of IL-31 present 
in patients’ serum. 
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STATEMENT OF PURPOSE 
In order to further elucidate the clinical heterogeneity of DEB and EBP, we studied 
one kindred with both of these phenotypes (Figure 1). The proband is a 19-year-old 
female of Italian descent who was referred to Yale Dermatology Associates at age 
five with new-onset pruritic lesions on her right medial malleolus and chin. Over 
time, the patient’s pruritus gradually worsened with extension of lesions to her 
extensor extremities bilaterally, the peri-umbilicus, the sacrum, and the upper mid-
back. No triggers were reported. She was otherwise healthy, without a history of 
atopy. Her parents are non-consanguineous and neither reported any history of atopy, 
skin fragility, or pruritic dermatoses. The proband’s grandmother developed similar 
lesions at age 47, which persisted for approximately ten years before mostly resolving 
spontaneously. The proband’s 15-year-old brother also developed a few pruritic 
papules at age 13, but was much less extensively affected. Meanwhile, her second 
cousins once removed and their father report only trauma-induced blistering. The 
objective of this study was to better characterize the genetic complexity of COL7A1 
mutations causing DEB and EBP in this kindred.  
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Figure 1. DEB and EBP phenotypes independently segregate in one kindred with 
incomplete penetrance. (A) Individuals in EBP kindred 100 show either an 
epidermolysis bullosa pruriginosa phenotype (black symbols) or a dominant 
dystrophic epidermolysis bullosa phenotype (grey symbols).  * indicates genetic 
analysis has been performed. 
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METHODS:  
This study protocol was approved by the Human Investigation Committee at Yale 
University. The proband (100-1), her immediate family members (100-2-5), and two 
members from her extended family (100-6, 100-7) were clinically examined by 
dermatologists between 1997 and 2011. Two family members reported to have DEB 
were unable to participate in this study (100-8, 100-9). 
  
In the proband, clinical diagnosis was verified with skin biopsies of lesional sites 
performed with local anesthetic. The biopsy specimens were embedded for light and 
electron microscopy by Yale Dermatopathology Labs (New Haven, CT). 
Immunofluorescence staining for collagen IV, VII, and keratin 14 was performed by 
Beutner Laboratories (Buffalo, NY). Complete blood count, IgE levels, thyroid 
function, renal function, AST/ALT, bilirubins, iron, and ferritin were tested in the 
proband to exclude alternative causes of pruritus.  
  
Genomic DNA was extracted from peripheral blood lymphocytes in the proband and 
immediate family members using phenol-chloroform extraction. Primer sets 
representing all 118 exons of COL7A1, including intron-exon boundaries, were 
generated with Primer3 (http://frodo.wi.mit.edu/primer3/) using the hg18 version of 
the genome masked to exclude DNA sequence repeats (GenomeMasker: 
http://bioinfo.ebc.ee/snpmasker/) as the template. We also generated primers for the 
five most common filaggrin mutations in European populations (R501X; 2282del4; 
3702delG; R2447X; and S3247X) (31) and for the previously reported promoter SNP 
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in MMP1 (rs1799750: (-)>G) hypothesized to account for the pruritus of EBP (25). 
Polymerase chain reaction was carried out on 50 ng of DNA using KAPA2G Fast 
Polymerase (Kapa Biosystems; Woburn, MA) and then sequenced. The sequences 
were compared to the human reference sequence (hg18, NCBI) utilizing Sequencher 
(Gene Codes; Ann Arbor, MI). A single sequence variant in COL7A1 was identified 
which was not found in SNP databases and in sequencing of 95 ethnically-matched 
unrelated controls without history of skin disease. 
  
Review of the literature was performed using PUBMED search term “epidermolysis 
bullosa pruriginosa” between June 2009 and October 2011 and results are 
summarized in Table 1. Forty-two papers were identified; thirteen papers were 
excluded either because the case presented was not affected with epidermolysis 
bullosa pruriginosa or because no genetic analysis was performed. Additional 
mutations were found using the International Dystrophic EB Patient Registry database 
(http://www.deb-central.org). Each mutation was then surveyed using the Human 
Gene Mutation Database (http://www.hgmd.org/) and recent reviews of COL7A1 gene 
(12,15) to determine if it had been previously reported to cause DEB. Any 
discrepancies between sources were resolved by referring to the original article 
reporting the mutation in question. 
 
Statement of contributions of authors:  
Anita Farhi was actively involved in patient recruitment, in acquiring HIC approval 
for this study, and in obtaining peripheral blood samples from the subjects of this 
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study. Carol Nelson-Williams extracted the DNA from the blood samples. Drs. 
Richard Antaya and Keith Choate performed the clinical characterization of all the 
subjects examined and the skin biopsies when appropriate. Dr. Earl Glusac performed 
the histopathological analysis of the skin biopsies. Dr. Michael Kashgarian performed 
the electron microscopy readings of the proband's biopsy. I designed and executed the 
study, performed all of the PCRs, and analyzed all of the DNA sequence readings. 
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RESULTS: 
On full skin examination, the proband displayed excoriated, lichenoid papules with 
milia coalescing into confluent plaques (Figure 2). There was no nail dystrophy and 
ancillary lab tests to evaluate for pruritus were all within normal limits. Skin tests for 
common food allergens and standard inhalants were negative, except for an allergic 
reaction to penicillin at age 9. Histopathology of her lesions showed a subepidermal 
cleft with milia and electron microscopy showed a subepidermal cleft with lysis and 
separation of collagen fibrils in the reticular dermis. There was no evidence of 
amyloid deposition. Direct immunofluorescence showed normal quantities and 
immunolocalization patterns of collagen IV, collagen VII, and keratin 14 (Figure 3). 
Altogether, these findings supported a diagnosis of EBP. 
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Figure 2. Clinical features of EBP in proband, 100-1. (A-C) Lichenoid papules and 
nodular prurigo-like lesions on shins bilaterally (A), dorsal hand (B), and upper back 
(C). Many papules are excoriated.  
 
 
 
Figure 3. Histologic features of EBP in proband, 100-1. EBP is characterized by 
subepidermal clefting and disruption of anchoring fibrils. (A) Hematoxylin and eosin 
stain of affected skin shows subepidermal clefting (black arrow) and milium, 20X. (B, 
C) Direct immunofluorescence staining shows normal pattern and amount of collagen 
IV and VII. (D) Electron microscopy of skin adjacent to a nodular lesion shows lysis 
and separation of collagen fibrils in the reticular dermis (white arrow). * indicates 
subepidermal cleft.   
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The only remnants of EBP in the propositus’ grandmother were macular scars on her 
upper back and intermittent clusters of pruritic papules on her upper extremities (Fig. 
4A). The proband’s brother had few, isolated pruritic papules on his dorsal hands, 
elbows, knees, and ankles (Fig. 4B). The proband’s second cousin once removed 
exhibited trauma-induced blistering, atrophic scarring, and few milia on his extensors 
(Fig. 4C). Her mother had no skin findings on full skin examination. 
  
Figure 4. Clinical heterogeneity of EBP and DEB in kindred EBP 100. (A) Cluster 
of papules on the right hand of the proband’s maternal grandmother, 100-6. (B) 
Lichenoid papules on the left index finger of the proband’s 15-year-old brother, 100-4. 
(C) Blister and atrophic scarring on knee of the proband’s second cousin once 
removed, 100-7. 
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Sanger sequencing of COL7A1 in this kindred revealed a novel heterozygous splice 
site mutation in intron 47, c.4668+1 G>A, in the proband, her affected family 
members, and her unaffected mother (Figure 5). This mutation abolishes the intron 47 
splice donor; similar mutations frequently lead to exon skipping or use of cryptic 
splice sites nearby (9,16,18,19). Fifty-six mutations causing EBP are reviewed in 
Table 1 and Figure 6. All of the dominant mutations, including c.4668+1 G>A, 
interfere with the consecutive Gly-X-Y repeats in the triple helical domain of the 
protein. Only ten recessive cases were identified. 
 
  
Figure 5. DEB and EBP phenotypes result from the same COL7A1 mutation with 
incomplete penetrance. Sanger sequencing of exons and intron/exon boundaries of 
COL7A1 was performed. (A) WT junction between exon 47 and intron 47 shows 
position of normal splice donor. (B) A heterozygous c.4668+1 G>A mutation 
abolishes the intron 47 splice donor in all individuals with EBP (100-1, 4, 6), in a 
single individual with DEB (100-7), and in the unaffected mother of the index case 
(100-2). Wild type sequence was present at this position in the unaffected father (100-
3) and unaffected sibling (100-5) of the index case. 
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Mutation Exon Effect 
Previously 
reported to 
cause DEB? 
Age of onset Ethnicity Sex IgE level Other affected family members? Reference 
p.R28G/ 
p.G2366A 1/92 
Missense/ 
Missense 
G2366N: 
RDEB-O 
DEB since 8 
y/o; EBP 
developed 
after first 
pregnancy 
Italian F Normal 
Brother with nail-
dystrophy-only 
DEB 
Pruneddu, 
2010 
p.R51G/ 
p.R2492X 2/98 
Missense/ 
PTC 
c.7474C>T: 
RDEB-O 13 y/o Italian M Normal None Drera, 2006 
c.425A>G/ 
c.7344G>A 3/95 
Splice 
PTC/  
Splice PTC
Both: 
RDEB-O 12 y/o Italian F Normal None Drera, 2006 
c.425A>G/ 
p.E2736K 3/110 
Splice 
PTC/ 
Missense  
c.425A>G: 
RDEB-O 
DEB since 6 
y/o; EBP 
developed at 
53 y/o 
Caucasian M Normal None Schumann, 2008 
c.497insA/ 
p.G1347W 4/34 
PTC/ 
Missense 
c.497insA: 
RDEB-sev 
gen 
G1347N: 
RDEB-O 
8 y/o Caucasian F Normal None Schumann, 2008 
c.4668+1 G>A 47 
In-frame 
exon 
skipping  
No 5 y/o Italian F Normal 
Multiple family 
members w/ DDEB 
spectrum 
This report 
p.G1572A/ 
c.7787delG 48/104 
Missense/ 
PTC No NA NA NA NA NA 
Almaani, 
2011 
p.R1630X/ 
c.7344G>A 51/95 
Nonsense/  
Splice PTC
R1630X: 
RDEB-sev 8 y/o Italian F Normal None Drera, 2006 
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gen 
c.7344G>A: 
RDEB-O 
p.R1630X 51 Nonsense RDEB-sev gen 1 y/o Caucasian F Normal None 
Schumann, 
2008 
c.5399+1G>C In. 55 
In-frame 
exon 
skipping  
No 6 y/o Caucasian M NA 
Mother and sister 
w/ toenail 
dystrophy-only 
DEB 
Tey, 2011 
p.G1755D 59 Missense No NA NA NA NA NA Posteraro, 2005 
p.G1755D 59 Missense No 39 y/o Italian F Normal None Drera, 2006 
p.G1755D 59 Missense No 8 y/o Turkish F Normal 
Mother with nail-
dystrophy-only 
DEB 
Schumann, 
2008 
p.G1770D 61 Missense RDEB NA NA NA NA NA Almaani, 2009 
p.G1773R 61 Missense DDEB 9 y/o Chinese M Normal 
Mom and maternal 
grandfather w/ 
mild phenotype 
Jiang, 2011 
p.G1791E 61 Missense No Infancy Caucasian F NA None Mellerio, 1999 
c.5532+1G>A/ 
c.7786delG 
In 64/ 
Ex104 
In-frame 
exon 
skipping/ 
PTC 
c.7786delG: 
RDEB-O Infancy Caucasian F NA None 
Mellerio, 
1999 
p.G1860R 66 Missense No NA NA NA NA NA Almaani, 2009 
p.G1913R 69 Missense No NA NA NA NA NA Almaani, 
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2009 
p.Q1924P/ 
c.6619-2A>T 
Ex 69/ 
In 82 
Missense/  
In-frame 
exon 
skipping 
No NA Middle Eastern NA NA NA 
Abu Sa’d, 
2006 
p.G2028R 73 Missense 
DDEB and 
RDEB 
 
20 y/o Japanese F NA 
Father, aunt, and 
paternal 
grandmother with 
EBP 
Murata, 
2000 
p.G2028R 73 Missense 
DDEB and 
RDEB 
 
DEB since 1 
y/o; EBP 
developed at 
18 y/o 
Caucasian F Normal 
Grandmother, 
brother, and 
daughter with DEB 
Schumann, 
2008 
p.G2034R 73 Missense DDEB NA Chinese NA NA NA Chen, 2000 
p.G2034W 73 Missense DDEB 
DEB since 
birth; EBP 
developed at 7 
y/o 
Caucasian F Normal 
Grandmother, 
father, and sister 
have DEB 
Schumann, 
2008 
p.G2037E 73 Missense DDEB NA NA NA NA NA Unpublished
p.G2040D 73 Missense DDEB Infancy Caucasian F Elevated None Ozanic, 2005 
p.G2073V 75 Missense RDEB-O 10 y/o Italian F Elevated Father with EBP Drera, 2006 
p.G2079R 75 Missense No NA NA NA NA NA Abu Sa’d, 2006 
p.G2159E 79 Missense No NA NA NA NA NA Almaani, 2009 
p.G2210V/ 
p.G2791W 83/113 
Missense/ 
Missense 
G2791W: 
DDEB NA Aboriginal NA NA 
Multiple family 
members w/ 
DDEB-Pr and 
Dang, 2007 
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Pasini subtype 
p.G2213R 83 Missense RDEB 37 y/o Caucasian F NA NA Almaani, 2009 
c.6652-2A>G 83 
In-frame 
exon 
skipping 
No NA NA NA NA NA Abu Sa’d, 2006 
p.G2239D 85 Missense No NA NA NA NA NA Tamai, 1998
p.G2239V 85 Missense No NA NA NA NA NA Almaani, 2011 
p.G2242E 85 Missense No NA NA NA NA NA Tamai, 1998
p.G2242E 85 Missense No 12 y/o Japanese F NA 
Son w/ bullous 
dermolysis of the 
newborn 
Murase, 
2011 
p.G2242R 85 Missense No Teens Chinese F NA 
Father, brother, 
aunt, and cousin 
affected with mild 
EBP 
Lee, 1997 
p.G2242R 85 Missense No 7 y/o Caucasian M NA Father with mild EBP 
Mellerio, 
1999 
p.G2242W 85 Missense No 10 y/o Chinese M Elevated 
Father, 
grandfather, and 
paternal uncle with 
EBP 
Shi, 2009 
p.G2251E 86 Missense DDEB 25 y/o Chinese F Normal 
4 siblings and 
mother with EBP; 
2 unaffected 
siblings with 
mutation 
Ee, 2007 
p.G2251E 86 Missense DDEB 1 month old Japanese M NA Unaffected father Takayashi, 
  
22
w/ mutation 2011 
c.6846G>C 87 
In-frame 
exon 
skipping 
No 3 kindreds Danish NA NA 
Multiple family 
members w/ 
blistering and nail 
dystrophy 
Covaciu, 
2011 
p.G2287R 87 Missense DDEB 71 y/o Japanese M Normal None Hayashi, 2011 
c.6863del16 87 PTC No 11 y/o Hispanic M NA 
Daughter with mild 
EBP; 5 generation 
family with DEB 
Mellerio, 
1999 
p.G2290A 87 Missense No 40s Caucasian F NA NA Almaani, 2009 
c.6899+2A>G 87 
In-frame 
exon 
skipping 
No < 35 yo Chinese M NA 18 other family members with EBP Jiang, 2002 
c.6900+1G>T In. 87 
In-frame 
exon 
skipping 
DEB 2 month old Chinese M Normal 11 other family members with EBP Ren, 2007 
c.6900+1G>C In. 87 
In-frame 
exon 
skipping 
No 20 y/o Chinese M Normal Multiple affected family members Jiang, 2011 
c.6900+2delTGAT In. 87 
In-frame 
exon 
skipping 
No 30 y/o Italian F Elevated 
16 members in 5 
generations with 
skin lesions 
Drera, 2006 
c.6900+4A>G In. 87 
In-frame 
exon 
skipping 
RDEB-sev 
gen 38 y/o Italian F Normal 
5 other affected 
members in 4 
generations with 
skin lesions 
Drera, 2006 
p.G2360R 92 Missense No NA NA NA NA NA Almaani, 
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2011 
p.G2366V 92 Missense RDEB-O 20s Chinese F 
Normal in 
proband; 
elevated in 
son 
Son and daughter 
with EBP 
Chuang, 
2004 
p.G2369S 93 Missense RDEB 17 y/o Pakistani M NA None Mellerio, 1999 
p.G2508D 100 Missense No NA NA NA NA NA Almaani, 2011 
p.G2517D 100 Missense No NA NA NA NA NA Almaani, 2011 
p.G2623V 105 Missense RDEB-O and DDEB 8 y/o Caucasian M Normal Brother with DEB 
Schumann, 
2008 
p.G2626D 106 Missense No 2 y/o Chinese F NA 
4-generation 
family with skin 
lesions 
Wang, 2007 
p.G2680D 108 Missense No NA NA NA NA NA Almaani, 2011 
p.G2701W 109 Missense No 25 y/o Chinese F Normal Unaffected mother w/ mutation Jiang, 2011 
p.G2713R 110 Missense DDEB 29 y/o Caucasian F NA Father and nephew with DEB 
Mellerio, 
1999 
p.G2713R 110 Missense DDEB 27 y/o Turkish F NA None Broekaert, 2006 
p.G2719D 110 Missense No 6 y/o Caucasian F NA Brother and mother Riedl, 2009 
 
Table 1. Reported EBP mutations organized by position within COL7A1. We found 61 reports of EBP. In 27 cases, other family members 
were affected with DEB and its variants. Of the 56 different mutations found, only 34 mutations were not previously reported to cause either 
DDEB or RDEB. All probands have unifying features of pruritus, lichenoid papules, and/ or prurigo-like nodules most commonly on the shins. 
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Many additionally presented with milia and nail dystrophy. Missense mutations are denoted using protein nomenclature while other mutations 
consisting of, but not limited to, splice site mutations, insertions, and deletions are denoted using the coding sequence. AR = autosomal 
recessive; AD = autosomal dominant; DDEB = dominant dystrophic epidermolysis bullosa; RDEB-sev gen = severe generalized recessive 
dystrophic epidermolysis bullosa; RDEB-O = generalized other recessive dystrophic epidermolysis bullosa; In = intron; X = termination codon; 
N = any protein; NA = not available; ND = not detected.  
 
 
Figure 6. COL7A1 mutations reported to 
cause EBP. Fifty-six mutations are 
represented. Missense and nonsense 
mutations are represented using the protein 
sequence whereas splicing mutations, 
deletions, and insertions are represented 
using the cDNA sequence. The mutation 
identified in this family is bolded and 
denoted by an asterisk (*). Recessive 
mutations appear above the protein 
schematic and dominant mutations appear 
below. 
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Recognizing that filaggrin mutations could modify the phenotypes observed in this 
kindred (30,31), we performed sequencing of the five most common FLG variants in 
the European population in our patient and found none. We also addressed the 
findings of another group which suggested that a promoter SNP in MMP1 leads to an 
imbalance of collagen degradation secondary to overexpression of matrix 
metalloproteinase 1 with ensuing inflammation and pruritus (25,32). Sequencing of 
the proposed transcription factor binding site (rs1799750: (-)>G) of MMP1, however, 
did not reveal any sequence differences between the proband and her mother.  
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DISCUSSION:  
Intra-familial differences in clinical manifestations of EBP is well described in the 
literature (8,18,37,38). One member of the family might suffer from severe EBP while 
another from a milder EBP (17,20,39), nails-only DDEB (5,6,40), generalized DDEB 
(5,18,20), rarer variants of DEB (29,38), or even no phenotype at all (8,17,37). For 
EBP, this phenomenon has been attributed to a presumed adult onset, and attempts 
have been made to predict a phenotype in infants or children based on their genetic 
mutation and family history (8,21,29). However, the pattern is not consistent and 
others report affected children and a clinically unaffected parent carrying the mutation 
(37). In our case, although the proband and her brother presented in childhood, their 
grandmother developed EBP at age 47 and their 46-year-old mother currently has no 
skin findings despite carrying the same dominant mutation. 
 
The heterogeneity of phenotypes even within one family can be partially explained by 
the incomplete penetrance of COL7A1 gene mutations. In accordance with previous 
reports, no clear pattern emerged from our attempt to correlate COL7A1 gene 
mutations with disease phenotype. Most of the pathogenic mutations in EBP are 
dominant and within the triple helix, thus altering the Gly-X-Y amino acid triplet 
integral for collagen stability and tensile strength. Of the ten recessive cases found in 
our review of the literature, seven contain a combination of loss-of-function/gain-of-
function mutation, suggesting that the gain-of-function mutation is in reality the 
causative allele while the other allele includes a silent mutation or SNP (Table 2). 
Clinically, the mild blistering phenotype of EBP usually resembles that of DDEB 
  
27
more than RDEB and only rarely is quantitative or qualitative changes in type VII 
collagen noted upon biopsy. 
Case Mutation 1 (Effect) Mutation 2 (Effect) 
1 p.R28G (missense) p.G2366A (missense) 
2 p.R51G (missense) p.R2492X (PTC) 
3 c.425A>G (splice PTC) c.7344G>A (splice PTC) 
4 c.425A>G (splice PTC) p.E2736K (missense) 
5 c.497insA (PTC) p.G1347W (missense) 
6 p.G1572A (missense) c.7787delG (PTC) 
7 p.R1630X (nonsense) c.7344G>A (splice PTC) 
8 c.5532+1G>A (in-frame exon 
skipping) 
c.7786delG (PTC) 
9 p.Q1924P (missense) c.6619-2A>T (in-frame exon 
skipping) 
10 p.G2210V (missense) p.G2791W (missense) 
 
Table 2. Reported mutations causing recessive EBP. The majority of these cases 
have one mutant allele predicted to result in loss of function and a second gain of 
function mutant allele expected to contribute to disease phenotype, giving essentially 
mono-allelic expression. Exceptions include cases 1, 9, and 10 in which two gain-of-
function mutations are present. The mutations c.425 A>G, c.497insA, and R2492X 
are predicted to undergo nonsense-mediated decay and thus would not be expressed 
(41). In Case 10, the authors postulated that previously reported G2791W was the 
relevant mutation and that G2210V is a polymorphism found in Australian 
Aboriginals (38). The putative causative mutations are bolded, based on prior reports 
of the same mutation causing EBP or presumed deleterious effect on the encoded 
protein. 
 
Overwhelmingly, the EBP patients presented in the research literature and 
summarized in Table 1 are from institutions that can afford genetic sequencing, that 
is, those located in Western Europe, China and Japan, Australia, and the USA. Only a 
few case reports have been published from India, but none offer a genetic analysis and 
some did not perform the necessary biopsies to rule out other causes of the lesions 
such as lichen amyloidosis or prurigo nodularis (42,43). There is a dearth of genetic 
information known about populations in the Middle East, Africa, and South America, 
although these kindreds often present with unique COL7A1 mutations that may 
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perhaps lead to new insights regarding the phenotypic variability in this 
genodermatosis (44). 
 
The mutation identified in this study, c.4668+1 G>A, is located at the conserved 
splice site donor of intron 47, which we predict leads to in-frame exon 47 skipping 
based upon previous studies investigating splice site mutations (20,40,44). Although 
we did not confirm the altered protein product with reverse transcriptase PCR, we 
hypothesize that two mRNA products would be isolated from the proband and all 
other carriers of the heterozygous mutation. Exon 47 contains 11 amino acids and is 
located within the triple helix. Exclusion of this exon is expected to alter the stability 
of collagen VII anchoring fibrils in the papillary dermis. 
 
Notably, affected individuals can transition from a DEB to an EBP phenotype; most 
attribute this to the development of pruritus, which then, in turn, causes the lesions of 
EBP (5,6,9,24,27). This finding lends support to the question of whether EBP is a 
unique disease entity or whether the phenotype is due to pruritus superimposed on 
DEB (4,11,29). Although some patients report an initiating incident such as thyroid 
dysfunction or chickenpox infection, most EBP cases did not improve when the 
pruritic disease resolved and the majority of EBP patients do not remember an 
inciting factor (5). Thus, there may be an element of recall bias in these case reports, 
but larger trials are difficult to conduct given the rarity of EBP. In our kindred, neither 
the index case nor her brother is atopic, and although their grandmother developed 
hypothyroidism in her 30s, she was clinically euthyroid at the time of her EBP 
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eruption nearly fifteen years later. Yet, the question of whether itch is a symptom of 
EBP versus integral to the pathogenesis of EBP is still being debated. 
 
EBP is notoriously challenging to treat. Therapeutics reported to be successful in the 
literature include high-dose topical and oral corticosteroids (4,9), cyclosporine 
(33,40), topical tacrolimus (10,45), and thalidomide (46). However, none of these 
therapeutics work universally for patients with EBP. In a cohort of eight patients on 
tacrolimus, only one patient reported significant relief and three others reported partial 
relief (32). Corticosteroids has a similar, if not higher, failure rate (4,9) and the 
number of patients treated with cyclosporine is too few to gauge its efficacy.  The 
exact mechanisms by which these treatments affect EBP is still unknown, but the 
common endpoint among them is the dissolution of pruritus with improvement of the 
cutaneous lesions manifesting several months later (9,32,46). This observation leads 
to the possibility of new medications directed at novel targets as we learn more about 
the pathophysiology of pruritus.  
 
Our patient was treated with numerous medications including topical and systemic 
corticosteroids, anti-histamines, anti-opiates, capsaicin, TNFα inhibitors, and 
phototherapy with minimal success. Oral cyclosporine 5 mg/kg mildly improved her 
pruritus, but was discontinued after five months due to marked gingival hyperplasia. 
Low-dose thalidomide has been documented to improve EBP, most likely via 
immunomodulation of the production of TNFα, IFNγ, and other cytokines (46). Our 
patient was started on 100 mg/day thalidomide and reported decreased pruritus and 
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flattening of her lesions within two months. She developed mild peripheral 
neuropathy after four months of treatment so the dose was decreased to 50 mg/day 
with resolution of her paresthesias and continued efficacy. After nine months of 
thalidomide treatment, the proband’s pruritus is well-controlled and her lesions 
continue to flatten leaving hypopigmented macules and milia (Figure 7).  
  
 
Figure 7. Improvement of skin lesions with systemic thalidomide administration. 
The index case was started on thalidomide 100 mg daily and improved gradually with 
most apparent results at two months. Shins (A), left dorsal hand (B), and mid-upper 
back (C) show flattening of papules with less excoriation after six months of 
treatment. 
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Mutational analysis of COL7A1 gene in patients suspected of DEB is not currently 
used for diagnosis, but rather only for the purposes of research or for genetic 
counseling. As genetic sequencing becomes easier and more cost-effective, it is 
plausible that it will become more routinely used in clinical practice but the practical 
implications remain unclear. For severe RDEB, the gene has been identified as a 
possible target for modulation through allogeneic bone marrow transplantation or 
induced pluripotent stem cells and a few small clinical trials have shown improvement 
(47,48). However, the technology of correcting genetic mutations is still nascent, and 
the risk of morbidity and mortality greatly outweigh any potential benefit for patients 
with DDEB or EBP. In medical genetics, prenatal diagnosis has been heralded as a 
new area of intervention. This endeavor has been attempted for expectant parents with 
relatives affected by severe variants of EB such as RDEB and junctional EB and has 
been mostly accurate in identifying the mutation using current prenatal sampling and 
mutation detection methods (1,49). Yet, the variability of clinical severity in DEB 
displayed in our kindred and in others, even within RDEB, (18,25,38) suggest caution 
is needed in interpreting the results of mutational analysis. 
 
This case demonstrates the phenotypic complexity and incomplete penetrance of 
COL7A1 mutations in an extended kindred with DEB and EBP. The same mutation in 
intron 47, c.4668+1 G>A, resulted in a mild EBP in one individual, a severe but time-
limited course in another, and no effect in yet another, but caused severe EBP in the 
proband that responded to thalidomide treatment after more than ten years of trying 
alternative therapies. Additionally, the same mutation caused classic DEB with solely 
trauma-induced blistering in another branch of this family. Clinical studies and DNA 
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sequencing for five common European variants of filaggrin and an MMP1 promoter 
SNP failed to reveal the etiology of the proband’s pruritus. Given that the observed 
mutation is predicted to affect splicing, one might speculate that alternative splice 
isoforms are expressed in different members of this kindred, though this would not 
explain the phenotypic variability seen in the majority of EBP kindreds which carry 
missense mutations. We expect that genetic and/or environmental factors are involved 
in the initiation and progression of EBP, although the exact mechanisms remain to be 
determined. Further elucidation may become permissible with broader availability of 
whole genome and transcriptome sequencing and better understanding of common 
polymorphisms within the population that may contribute to the pathogenesis of 
pruritus and to EBP.  
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